<DOC>
	<DOC>NCT02262273</DOC>
	<brief_summary>This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. The objectives are to describe in a real-world population, treatment patterns, BRCA mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects</brief_summary>
	<brief_title>OSCA - Olaparib Standard of CAre Study</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1. First determined to have platinumsensitive recurrent serous ovarian cancer between January 1, 2009, and December 31, 2013 (study entry period), as defined by no evidence of disease progression for at least 6 months after completion of a firstline platinumbased chemotherapy regimen; the first date of platinumsensitive recurrence between January 1, 2009 and December 31, 2013 will define the study index date. 2. At least 18 years of age on the index date. 3. Fully documented medical history related to the patient's ovarian cancer treatment beginning with initial diagnosis of serous ovarian cancer. 4. Patients can be either alive or deceased at the time of medical record abstraction. 1. Ever taken an investigational product as part of an interventional clinical trial for ovarian cancer.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>women</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>recurrent</keyword>
	<keyword>serous</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>BRCA</keyword>
	<keyword>PARP</keyword>
	<keyword>Olaparib</keyword>
</DOC>